Hasford et al developed a simple score for evaluating the outcome of a patient with chronic myelogenous leukemia (CML) treated with imatinib. This can help to identify a patient who may benefit from more aggressive or a more novel therapy. The authors are from multiple hospitals in Europe and participants in the European Treatment and Outcome Study for CML (EUTOS).


Patient selection: CML treated with imatinib



(1) percent basophils in the peripheral blood smear (enter from 0 to 100)

(2) size of spleen as spn below the costal margin in centimeters ("as assessed by palpation")


EUTOS score =

= (7 * (percent basophils)) + (4 * (spleen size in cm))



• minimum score: 0

• maximum score: > 350

• A high score is associated with greater risk.




<= 87

low risk

> 87

high risk


X =

= (0.07 * (percent basophiles)) + (0.0402 * (spleen size)) - 2.1007


probability of no complete cytogenetic response =

= 1 / (1 + EXP((-1)*X))


A score of 87 corresponds to a probability of no complete cytogenetic response of 22.7%.


To read more or access our algorithms and calculators, please log in or register.